Evaluation of in vitro and in vivo therapeutic antitumor efficacy of transduction of polo‑like kinase 1 and heat shock transcription factor 1 small interfering RNA

Hattori,Yoshiyuki; Kikuchi,Takuto; Ozaki,Kei‑Ichi; Onishi,Hiraku

doi:10.3892/etm.2017.5060

Evaluation of in vitro and in vivo therapeutic antitumor efficacy of transduction of polo‑like kinase 1 and heat shock transcription factor 1 small interfering RNA

Authors:
- Yoshiyuki Hattori
- Takuto Kikuchi
- Kei‑Ichi Ozaki
- Hiraku Onishi
View Affiliations

Affiliations: Department of Drug Delivery Research, Hoshi University, Tokyo 142‑8501, Japan, Education and Research Center for Fundamental Pharmaceutical Sciences, Osaka University of Pharmaceutical Sciences, Osaka 569‑1094, Japan
Published online on: August 28, 2017 https://doi.org/10.3892/etm.2017.5060
Pages: 4300-4306
Copyright: © Hattori et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Mitotic progression is regulated by the phosphorylation of heat shock transcription factor 1 (HSF1) by polo‑like kinase 1 (PLK1); however, this interaction is often deregulated in tumors. High expression levels of PLK1 and HSF1 have been observed in various types of human cancer. In the present study, it was investigated whether small interfering (si)RNA against PLK1 or HSF1 could suppress tumor growth in vitro and in vivo. In vitro transfection of PLK1 and HSF1 siRNA into PKL1‑ and HSF1‑positive human breast tumor MDA‑MB‑231 and human cervical carcinoma HeLa cells inhibited cell growth via suppression of PLK1 and HSF1 mRNA expression, respectively. However, the transfection of PLK1 or HSF1 siRNA did not significantly affect the cytotoxicity of doxorubicin in HeLa cells. Furthermore, injection of PKL1 or HSF1 siRNA into mice with liver HeLa metastasis suppressed tumor growth. From these findings, PLK1 and HSF1 may be considered to be promising targets for antitumor therapy.

View Figures

View References

1	Sorger PK: Heat shock factor and the heat shock response. Cell. 65:363–366. 1991. View Article : Google Scholar : PubMed/NCBI
2	Morano KA and Thiele DJ: Heat shock factor function and regulation in response to cellular stress, growth, and differentiation signals. Gene Expr. 7:271–282. 1999.PubMed/NCBI
3	Wang Y, Theriault JR, He H, Gong J and Calderwood SK: Expression of a dominant negative heat shock factor-1 construct inhibits aneuploidy in prostate carcinoma cells. J Biol Chem. 279:32651–32659. 2004. View Article : Google Scholar : PubMed/NCBI
4	Calderwood SK: Heat shock proteins in breast cancer progression--a suitable case for treatment? Int J Hyperthermia. 26:681–685. 2010. View Article : Google Scholar : PubMed/NCBI
5	Schmucker S and Sumara I: Molecular dynamics of PLK1 during mitosis. Mol Cell Oncol. 1:e9545072014. View Article : Google Scholar : PubMed/NCBI
6	Kim SA, Yoon JH, Lee SH and Ahn SG: Polo-like kinase 1 phosphorylates heat shock transcription factor 1 and mediates its nuclear translocation during heat stress. J Biol Chem. 280:12653–12657. 2005. View Article : Google Scholar : PubMed/NCBI
7	Takai N, Hamanaka R, Yoshimatsu J and Miyakawa I: Polo-like kinases (Plks) and cancer. Oncogene. 24:287–291. 2005. View Article : Google Scholar : PubMed/NCBI
8	Knecht R, Elez R, Oechler M, Solbach C, von Ilberg C and Strebhardt K: Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck. Cancer Res. 59:2794–2797. 1999.PubMed/NCBI
9	Takahashi T, Sano B, Nagata T, Kato H, Sugiyama Y, Kunieda K, Kimura M, Okano Y and Saji S: Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers. Cancer Sci. 94:148–152. 2003. View Article : Google Scholar : PubMed/NCBI
10	Kim SA, Kwon SM, Yoon JH and Ahn SG: The antitumor effect of PLK1 and HSF1 double knockdown on human oral carcinoma cells. Int J Oncol. 36:867–872. 2010.PubMed/NCBI
11	Nakamura Y, Fujimoto M, Fukushima S, Nakamura A, Hayashida N, Takii R, Takaki E, Nakai A and Muto M: Heat shock factor 1 is required for migration and invasion of human melanoma in vitro and in vivo. Cancer Lett. 354:329–335. 2014. View Article : Google Scholar : PubMed/NCBI
12	Yao YD, Sun TM, Huang SY, Dou S, Lin L, Chen JN, Ruan JB, Mao CQ, Yu FY, Zeng MS, et al: Targeted delivery of PLK1-siRNA by ScFv suppresses Her2⁺ breast cancer growth and metastasis. Sci Transl Med. 4:130ra482012. View Article : Google Scholar : PubMed/NCBI
13	Zhang S, Zhi D and Huang L: Lipid-based vectors for siRNA delivery. J Drug Target. 20:724–735. 2012. View Article : Google Scholar : PubMed/NCBI
14	Simberg D, Weisman S, Talmon Y, Faerman A, Shoshani T and Barenholz Y: The role of organ vascularization and lipoplex-serum initial contact in intravenous murine lipofection. J Biol Chem. 278:39858–39865. 2003. View Article : Google Scholar : PubMed/NCBI
15	Hattori Y, Arai S, Kikuchi T, Ozaki K, Kawano K and Yonemochi E: Therapeutic effect for liver-metastasized tumor by sequential intravenous injection of anionic polymer and cationic lipoplex of siRNA. J Drug Target. 24:309–317. 2016. View Article : Google Scholar
16	Hattori Y, Arai S, Okamoto R, Hamada M, Kawano K and Yonemochi E: Sequential intravenous injection of anionic polymer and cationic lipoplex of siRNA could effectively deliver siRNA to the liver. Int J Pharm. 476:289–298. 2014. View Article : Google Scholar : PubMed/NCBI
17	Lee YJ, Kim EH, Lee JS, Jeoung D, Bae S, Kwon SH and Lee YS: HSF1 as a mitotic regulator: Phosphorylation of HSF1 by Plk1 is essential for mitotic progression. Cancer Res. 68:7550–7560. 2008. View Article : Google Scholar : PubMed/NCBI
18	Seth S, Matsui Y, Fosnaugh K, Liu Y, Vaish N, Adami R, Harvie P, Johns R, Severson G, Brown T, et al: RNAi-based therapeutics targeting survivin and PLK1 for treatment of bladder cancer. Mol Ther. 19:928–935. 2011. View Article : Google Scholar : PubMed/NCBI
19	Jacobs AT and Marnett LJ: HSF1-mediated BAG3 expression attenuates apoptosis in 4-hydroxynonenal-treated colon cancer cells via stabilization of anti-apoptotic Bcl-2 proteins. J Biol Chem. 284:9176–9183. 2009. View Article : Google Scholar : PubMed/NCBI
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
21	Sakurai Y, Hatakeyama H, Akita H and Harashima H: Improvement of doxorubicin efficacy using liposomal anti-polo-like kinase 1 siRNA in human renal cell carcinomas. Mol Pharm. 11:2713–2719. 2014. View Article : Google Scholar : PubMed/NCBI
22	Kato M, Hattori Y, Kubo M and Maitani Y: Collagenase-1 injection improved tumor distribution and gene expression of cationic lipoplex. Int J Pharm. 423:428–434. 2012. View Article : Google Scholar : PubMed/NCBI
23	Zhang XG, Lu XF, Jiao XM, Chen B and Wu JX: PLK1 gene suppresses cell invasion of undifferentiated thyroid carcinoma through the inhibition of CD44v6, MMP-2 and MMP-9. Exp Ther Med. 4:1005–1009. 2012. View Article : Google Scholar : PubMed/NCBI
24	Jiang S, Tu K, Fu Q, Schmitt DC, Zhou L, Lu N and Zhao Y: Multifaceted roles of HSF1 in cancer. Tumour Biol. 36:4923–4931. 2015. View Article : Google Scholar : PubMed/NCBI
25	Fang F, Chang R and Yang L: Heat shock factor 1 promotes invasion and metastasis of hepatocellular carcinoma in vitro and in vivo. Cancer. 118:1782–1794. 2012. View Article : Google Scholar : PubMed/NCBI